These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
535 related articles for article (PubMed ID: 9237184)
21. [Detection of HER-2/neu in breast carcinoma]. Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536 [TBL] [Abstract][Full Text] [Related]
22. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898 [TBL] [Abstract][Full Text] [Related]
23. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656 [TBL] [Abstract][Full Text] [Related]
24. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826 [TBL] [Abstract][Full Text] [Related]
25. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas. Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071 [TBL] [Abstract][Full Text] [Related]
26. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Latta EK; Tjan S; Parkes RK; O'Malley FP Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013 [TBL] [Abstract][Full Text] [Related]
27. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Afify AM; Werness BA; Mark HF Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445 [TBL] [Abstract][Full Text] [Related]
28. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens. Lin F; Shen T; Prichard JW Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744 [TBL] [Abstract][Full Text] [Related]
29. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154 [TBL] [Abstract][Full Text] [Related]
31. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
33. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Mezzelani A; Alasio L; Bartoli C; Bonora MG; Pierotti MA; Rilke F; Pilotti S Br J Cancer; 1999 May; 80(3-4):519-25. PubMed ID: 10408862 [TBL] [Abstract][Full Text] [Related]
34. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965 [TBL] [Abstract][Full Text] [Related]
35. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370 [TBL] [Abstract][Full Text] [Related]
36. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794 [TBL] [Abstract][Full Text] [Related]
37. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)]. Akhdar A; Bronsard M; Lemieux R; Geha S Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120 [TBL] [Abstract][Full Text] [Related]
38. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Press MF; Pike MC; Hung G; Zhou JY; Ma Y; George J; Dietz-Band J; James W; Slamon DJ; Batsakis JG Cancer Res; 1994 Nov; 54(21):5675-82. PubMed ID: 7522962 [TBL] [Abstract][Full Text] [Related]
39. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826 [TBL] [Abstract][Full Text] [Related]
40. Assessing sequential oncogene amplification in human breast cancer. Janocko LE; Lucke JF; Groft DW; Brown KA; Smith CA; Pollice AA; Singh SG; Yakulis R; Hartsock RJ; Shackney SE Cytometry; 1995 Sep; 21(1):18-22. PubMed ID: 8529465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]